The proteasome plays a pivotal role in controlling cell proliferation, apoptosis, and differentiation in a variety of normal and tumor cells. PS-341, a novel boronic acid dipeptide that inhibits 26S proteasome activity, has prominent effects in vitro and in vivo against several solid tumors. We examined its antiproliferation, proapoptotic effects using three human glioblastoma multiforme (GBM) cell lines and five primary GBM explants. PS-341 markedly inhibited proliferation of GBM cell lines and explants in liquid and soft agar culture. These cells developed a G2/M cell cycle arrest with a concomitant decreased percentage of cells in S phase (E2-fold), associated with an increased expression of p21 WAF1 , p27 KIP1 , as well as cyclin B1 and decreased levels of CDK2, CDK4, and E2F4. About 35-40% of the cells became apoptotic when exposed to PS-341 (10 À7 M, 24-48 h) as shown by Annexin V analysis; in concert with these findings, immunobloting showed a C-terminal 85 kDa apoptotic fragment of poly ADP-ribose polymerase (PARP), and a decreased level of Bcl2 and Bcl-xl. PS-341 downregulated the expression of Bcl-2 and Bcl-xl in protein levels at an early time of treatment. These changes occurred irrespective of the p53 mutational status of the cells. PS-341 activated JNK/c-Jun signaling in GBM cells, and the JNK inhibitor SP600125 blocked the JNK signaling to reverse partially the PS-341 growth inhibition. PS-341 (10 À7 M, 24 h) decreased nuclear NF-jB levels as shown by Western blot, and reduced transcriptional activity of NF-jB as measured by reporter assays in these transformed cells. Also, PS-341 enhanced TRAIL (TNF-related apoptosis-inducing ligand) and TNFa (tumor necrosis factor alpha) induced cell death and apoptosis (two-to five-fold) in GBM cells. In summary, PS-341 has profound effects on growth and apoptosis of GBM cells, suggesting that PS-341 may be an effective therapy for patients with gliomas.
Introduction
The ubiquitin-proteasome pathway is involved in proteolysis of most nuclear and cytosolic proteins, and in particular, many of the short-lived regulatory proteins that govern growth, activation, and signaling. The proteasome, therefore, represents a novel target for cancer therapy. PS-341 (Velcade/bortezomib) is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome . The antitumor effects of PS-341 have been extensively studied in mutiple myeloma (MM) with inactivation of nuclear factor-kB (NF-kB) being one of its major modes of action. The disease improved in many MM patients taking the drug (Hideshima et al., 2001 (Hideshima et al., , 2003 LeBlanc et al., 2002; Mitsiades et al., 2002; Orlowski et al., 2002) .
Preclinical studies have shown that this compound has antitumor activity against a variety of solid tumors, including carcinomas of the breast (Teicher et al., 1999) , lung (Ling et al., 2003) , colon (Cusack et al., 2001) , bladder (Johnson et al., 2003) , ovary (Frankel et al., 2000) , pancreas (Nawrocki et al., 2002) , and prostate (Frankel et al., 2000) . Sensitivity of glioblastoma multiforme (GBM) to PS-341 has not been extensively studied.
GBM is the most malignant, invasive, difficult to treat primary brain tumor. This form of cancer has a rapid growth rate, being capable of doubling in size within 10-20 days. Successful treatment of GBM is rare; standard therapies result in a mean survival of only about 10-12 months. In the present study, the antiglioma activity of PS-341 was examined using three human GBM cell lines and five primary GBM explants. The drug (10 À7 M, 2 days) caused GBM cells to growth arrest in the G2/M phase of the cell cycle, which was associated with 35-40% cells becoming apoptotic. Our data suggest that besides inhibition of NF-kB, activation of the JNK/c-Jun signaling pathway may be another mechanism by which PS-341 causes apoptosis of GBM cells. When combined with either tumor necrosis factor alpha (TNFa) or TNF-related apoptosis-inducing ligand (TRAIL), PS-341 enhanced the antiproliferation effects of these apoptotic stimuli. Taken together, PS-341 is highly effective against GBM in vitro, and may have a role in the therapy of this difficult to manage disease.
Results

PS-341 inhibited cell proliferation and clonal growth independent of p53 mutational status in GBM cells
The mutational status of p53 in the GBM cells was detected by single-strand conformation polymorphism (SSCP) analysis and nucleotide sequencing: Those with p53 mutations included T98G (M237I), U118 (R273H), U343 (R213Q), YK163 (V203L), JM94 (R273C); and those with wild-type p53 were U87, DA66, and MM156 (data not shown). We examined the effect of PS-341 (10 À9 -10 À6 M, 48 h) on cell proliferation of GBM cells in liquid culture using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. PS-341 produced a dose-dependent inhibition of growth of the three permanent GBM cell lines (U87 (p53 wt), T98G (p53 mt), and U343 (p53 mt)) and the two GBM explants (MM156 (p53 wt), YK163 (p53 mt)). Among these cell lines, T98G with mutant p53 was the most sensitive (ED 50 D9 Â 10 À9 M), while the ED 50 for the other p53 mutant lines, YK163 and U343, were 1 Â 10 À7 and 8 Â 10 À7 M, respectively. The ED 50 for U87 and MM156 with wild-type p53 were approximately 8 Â 10
À8
and 10 À7 M, respectively (Figure 1 ). When the GBM cell lines (U87 (p53 wt), T98G (p53 mt)) and GBM explants (DA66 (p53 wt), JM94 (p53 mt)) were cultured in soft agar either with or without PS-341, clonal growth was inhibited significantly by PS-341 (Figure 2) . Dose-response studies using T98G and JM94 showed an ED 50 of approximately 6 Â 10 À9 and 1.6 Â 10 À8 M, respectively (Figure 2 ). In summary, PS-341 inhibited growth of GBM cell lines and explants in liquid and soft agar culture with mean ED 50 for PS-341 ranging from 10 À8 to 10 À6 M, and sensitivity of the GBM cells to the compound was independent of their p53 status.
PS-341 increased percentage of GBM cells in G2/M, decreased those in S phase and induced expression of cell cycle-related proteins
To understand the mechanism of action of PS-341, we initially studied the cell cycle distribution by flow cytometry in three GBM cell lines and three GBM explants. The percentage of cells in the G2/M phase increased about two-fold in all six GBM cell lines and explants after their exposure to PS-341 for 6-12 h (Figure 3) . The percentage of cell in S phase decreased about two-fold in five of the six cell lines and explants after their exposure to PS-341 for 24-48 h.
PS-341 (10 À7 M, 3, 9, 24 h) caused the accumulation of cyclin-dependent kinase inhibitors p21 WAF1 , p27 KIP1 , and G2/M phase control protein cyclin B1 in the GBM cell lines (U87 and T98G, Figure 4a and b) and GBM explants (DA66 and JM94, Figure 4c Western blotting showed that protein levels of Bcl-2 decreased about 50% at 3 h, and 90% at 9 and 24 h. However, the mRNA of Bcl-2 as measured by real-time RT-PCR decreased about 50% at 9 and 24 h. Parallel findings were observed for Bcl-xl. These results suggest that the early effect of PS-341 is to decrease protein levels of Bcl-2 and Bcl-xl followed by a decrease of both protein and RNA expression of these genes.
PS-341 activated JNK/c-Jun signaling in GBM cells, and JNK inhibitor SP600125 blocked signaling of JNK protecting cells from growth inhibition mediated by PS-341
We explored by Western blot analysis whether PS-341 could induce phosphorylation of JNK and c-Jun in GBM cells. PS-341 (10 À7 M) caused the phosphorylation of both JNK and c-Jun (Figure 7 ). Phosphorylation was noted by 3 h but massive phosphorylation of both proteins occurred by 24 h in all four GBM cell lines and explants.
To study the role of the JNK/c-Jun signal pathway in the PS-341-induced growth arrest of GBM cells, this pathway was blocked using the JNK-specific inhibitor SP600125. In the presence of SP600125, the phosphorylation of JNK and c-Jun mediated by PS-341 was markedly decreased in T98G cells (Figure 8a ). These results suggest that the JNK inhibitor SP600125 effectively blocked the JNK/c-Jun signal pathway. In further experiments, T98G cells were cultured with PS-341 (10 À7 M) either alone or in combination with SP600125 (4 Â 10 À5 M) for 1 day. SP600125 blunted the 
Effect of PS-341 on NF-kB in GBM cells
One of the major effects of proteasome inhibition in many cell types is the reduction of NF-kB translocation to the nucleus, due to blocking of the cytosolic degradation of IkB. In order to assess the effects of PS-341 on NF-kB activation in GBM cells, the IkB protein level was examined by Western blotting, and was found to accumulate in each of the two GBM cell lines and the two GBM explants that we examined (Figure 9a-d) . Furthermore, immunoblotting results showed that nuclear NF-kB levels decreased in T98G, which had been cultured with PS-341 (1 Â 10 À7 M, 24 h) compared to control untreated cells (Figure 9e ). We also transfected the T98G GBM cells with an NF-kB promoter coupled to a luciferase reporter construct. Exposure of these cells to PS-341 (10 À7 M, 24h) decreased their levels of NF-kB activity by about 50% (Figure 9f ).
Drug interactions between the PS-341 and either TNFa or TRAIL in GBM
The ability of TRAIL and TNFa to induce apoptotic death of GBM cells was enhanced by PS-341 (Figure 10 ). T98G cells were cultured with PS-341 (10 À8 M or 5 Â 10 À8 M) combined with either TRAIL (10, 20 ng/ ml) (Figure 10a , Po0.001 compared to either agent alone, t-test) or TNFa (50, 100 ng/ml) (Figure 10b , Po0.01 compared to either agent alone, t-test). Both the MTT and annexin-V assay showed that the ability of TRAIL and TNFa to induce cell death and apoptosis was enhanced two-to five-fold by PS-341 in these GBM cells (Figure 10 ).
Discussion
Boronated proteasome inhibitors, such as PS-341, are more potent than their structurally related aldehydes (Ling et al., 2003) . In vitro screening data using a panel of 60 human tumors cell lines indicated that PS-341 has significant growth inhibitory activity against a wide variety of tumors . Other proteasome inhibitors, such as the calpain inhibitor, lactacystin, MG132, and AcLLNal, also inhibit glioma cell growth (Kitagawa et al., 1999; Wagenknecht et al., 1999; Tani et al., 2001) . However, little has been reported of the effect of PS-341 on GBM cells. We found that cell growth of three of the GBM cell lines and five of the GBM explants were growth inhibited in liquid and soft agar culture by PS-341 (ED 50 , 10 À8 -10 À6 M). Prior investigations have shown that PS-341 blocked cells of several types of solid tumors in the G2/M phase of the cell cycle Sunwoo et al., 2001; Ling et al., 2002 Ling et al., , 2003 Nawrocki et al., 2002) . In this study, both the GBM cell lines and explants cultured with PS-341 accumulated in the G2/M phase associated with their increased levels of p21 WAF1 , p27 KIP1 , and cyclin B1. Previous studies using other proteasome inhibitors found that expression of p21 WAF1 and p27 KIP1 increased in glioma cells (Kitagawa et al., 1999; Wagenknecht et al., 1999) . Furthermore, we found that levels of CDK2 and CDK4, as well as, E2F4 decreased ( Figure 4 ) consistent with the cells exiting the cell cycle.
The p53 protein plays an important role in cell cycle regulation and apoptosis (Kuerbitz et al., 1992; Wu and Levine, 1994) . Several studies suggested that proteasome inhibitors induced apoptosis and inhibited growth of tumor cells in a p53-independent manner (Shinohara et al., 1996; Kitagawa et al., 1999; Wagenknecht et al., 1999) ; others have suggested these effects occurred in a p53-dependent (Lopes et al., 1997) or partly dependent fashion (Ling et al., 2003) . We found that both the p53-wt and -mutant GBM cell lines and explants were sensitive to growth inhibition and apoptosis mediated by PS-341. About 35% of GBMs have mutant p53 (Gallou et al., 2001) , emphasizing the importance of selecting a therapy that can function independent of the p53 mutational status of the tumors.
Stress stimuli can activate either the stress-activated protein kinase (SAPK) or JNK to induce apoptosis (Verheij et al., 1996) . Previous studies have shown that PS-341-induced apoptosis was associated with activation of JNK in MM cells and lung cancer cells (Hideshima et al., 2003; Yang et al., 2004) . Blocking JNK by a specific JNK inhibitor, SP600125, abrogates PS-341 induction of apoptosis in prostate cancer (Yang et al., 2004) . We found that PS-341 markedly stimulated phosphorylation of JNK and c-Jun in GBM cells, and the JNK inhibitor SP600125 blocked both this phosphorylation and partly blocked the cell death mediated by PS-341. These results suggested that JNK/c-Jun signaling pathway is in part involved in the apoptosis induced by PS-341.
One common feature of most GBM is a hyperactive NF-kB pathway (Hayashi et al., 2001) , and the rate of growth of these cells paralleled the activity of this pathway in these tumors (Nagai et al., 2002) . Therefore, this pathway becomes an important therapeutic target for these tumors. NF-kB activation depends on the signal-induced phosphorylation and ubiquitination of Our study demonstrated that PS-341 could significantly decrease the nuclear activity of NF-kB in GBM. Previous studies have shown that activation of NF-kB can inhibit apoptosis induced by a number of stimuli (Wang et al., 1998) . Both TRAIL and TNFa can bind to their respective receptors, and activate the caspase apoptotic pathway, as well as, stimulate NF-kB activation (Franco et al., 2001; Dai et al., 2003) . Proteasome inhibitors can block the stimulation of NF-kB while leaving the activation of the caspase pathway intact, explaining that PS-341 may enhance TNFa and TRAIL cell death (Franco et al., 2001; An et al., 2003) (Figure 11 ). In our studies, PS-341 markedly increased apoptosis of the GBM cell lines treated with either TNFa or TRAIL, suggesting that PS-341 may be a clinically useful adjunct to therapy with TRAIL and TNFa-like drugs.
In summary, we have demonstrated that PS-341 has profound effects on GBM cells including inhibiting their growth in liquid culture and their clonogenic proliferation in soft agar. This was accompanied by their accumulation in the G2/M phase of the cell cycle with increased levels of p21 WAF1 , p27 KIP1 , and cyclin B1 decreased expression of CDK2, CDK4, and E2F4 in a p53-independent fashion. In conjunction with these changes, activation of NF-kB was blunted, and JNK and c-Jun underwent marked phosphorylation. These events cumulated in apoptosis. These findings suggest that PS-341 may have a niche in the therapy of glioblastomas.
Materials and methods
Glioma cell lines and primary cell cultures
Human GBM cell lines U87 (p53 wild type (p53 wt)), T98G (p53 mutant (p53 mt)), U118 (p53 mt) were maintained in Dulbecco's modified Eagle's medium (Gibco, BRL) with 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA, USA), PS-341 increased IkB and decreased both the level of nuclear NF-kB and its transcriptional activity in GBM cells. Panels ad: U87 (p53 wt) and T98G (p53 mt) GBM cell lines as well as DA66 (p53 wt) and JM94 (p53 mt) GBM explants were cultured with PS-341 (10 -7 M) for 0, 3, 9, 24 h and Western blotted for levels of IkB. Panel e: T98G cells were cultured either without (À) or with ( þ ) PS-341 (10 À7 M, 24 h). Nuclear protein was extracted, Western blotted and probed for NF-kB and hnRNP (nuclear protein examined as control for equal loading). Panel f: The construct (NF-kB-Luc) containing four copies of NF-kB-binding sites attached to pGL3 luciferase reporter plasmid (top panel) was transiently transfected with p-RL-SV40-Luciferase (renilla luciferase) plasmid into T98G cells. After 3 h, cells were treated with either PS-341 (10 À7 M) or control diluent for 24 h, and luciferase activity was measured. Results represent mean7s.d. of three experiments with triplicate dishes per experimental point PS-341 induces growth arrest and apoptosis in GBM D Yin et al 10 U/ml penicillin-G, and 10 mg/ml streptomycin (Gemini Bio-Products, Calabasas, CA, USA). Primary GBM explants (DA66 (p53 wt), JM94 (p53 mt), MM156 (p53 wt), YK163 (p53 mt), BB184 (p53 wt)) were established from patients with GBM undergoing surgery. Written informed consent for research use of tumor tissue was obtained from each patient prior to surgery, according to a protocol approved by the institutional ethics committee. Tumor specimens were immediately transported to the laboratory, finely minced to single-cell suspension and cultured in complete medium (Ham's F-12/DME High Glucose medium (Irvine Scientific, Santa Ana, CA, USA) containing 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA, USA), 10 U/ml penicillin-G, and 10 mg/ml streptomycin (Gemini Bio-Products, Calabasas, CA, USA) and 2 mM glutamax-1 (Invitrogen, CA, USA)) into 100 cm 2 tissue culture plastic dishes. Cells were then collected and aliquots were cryopreserved in liquid nitrogen. One aliquot of cells was kept in culture and grown to confluence. Cells used in these experiments were subcultured for no more than 10 additional passages. All cells were incubated at 371C in 5% CO 2 . For clonogenic assays, cells were plated into 24-well flat-bottomed plates using a two-layer soft agar system with a total of 1 Â 10 3 cells/well in a volume of 400 ml/well, as described previously (Munker et al., 1986) . After 14 days of incubation, the colonies were counted.
Chemicals
Proteasome inhibitor PS-341 was obtained from Millennium Pharmaceuticals (Cambridge, MA, USA), and dissolved in DMSO at a stock concentration of 10 À2 M and stored at À201C. Fresh dilutions in medium were made for each experiment.
Cell proliferation
The cells were placed into 96-well plates at 2.0 Â 10 3 cells/well, and cell proliferation was measured at various times by MTT assay according to the protocol provided by Roche Molecular Biochemicals (Basel, Switzerland). 
Western blot
Cells were harvested for total cell lysates with RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5) containing a mixture of protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) as well as 1 mM NaF and 1 mM NaVO 4. Cell lysates were centrifuged at 13 000 r.p.m. for 10 min at 41C. Supernatant was collected, and the protein concentration was measured. The procedure for the nuclear protein extraction was carried out according to the manufacturer's instructions (CelLytic Nuclear Extraction Kit (Sigma)). Cells were swelled with hypotonic buffer, and then disrupted. The cytoplasmic fraction was removed, and the nuclear protein was released from the nuclei by a high salt buffer. The lysates (30 mg) were denatured in the sample buffer (10% glycerol, 5% b-mercaptoethanol, 2.3% SDS, 62.5 mM Tris-HCl, pH 6.8) by boiling and then subjected to 4-15% SDS-PAGE followed by electrotransfer to polyvinylidene difluoride membrane. The immune complexes were visualized with Supersignal West Pico Chemiluminescent Substrate or Supersignal west dura extended duration substrate (Pierce, Rockford, IL, USA) and normalized by internal control (GAPDH). The antibodies were bought from Santa Cruz Biotechnology Inc. (CA, USA).
Detection of p53 mutations
Presence of p53 gene mutations was detected by single-strand conformation polymorphism (SSCP) as description in a prior study (Imai et al., 1994) . The p53 gene was analysed for mutations in exons 5-8, which encompasses the region that is most frequently mutated, and all aberrantly migrating bands were DNA sequenced.
Cell cycle analysis
GBM cells (BB184, DA66, JM94, T98G, U118, U87) were placed in six-well dishes, cultured for 0, 3, 6, 12, 24, 36, 48 h with PS-341 (10 À7 M). After being trypsinized and washed twice with ice-cold phosphate-buffered saline (PBS), cells were fixed in 70% ice-cold ethanol overnight. The samples were treated by RNAase A and exposed to propidium iodide (PI), then analysed by flow cytometry (FACScan, Becton Dickinson).
Assessment of apoptosis
To study induction of apoptosis, annexin V assays (Annexin V-FITC Apoptosis Detection Kit; Pharmingen, San Diego, CA, USA) were performed according to the manufacturer's instructions. Briefly, cells were harvested after exposure to reagents, washed twice with PBS, incubated with FITCconjugated annexin V and PI for 15 min, and measured by FACScan (Becton Dickinson).
RNA isolation and RT-PCR
U87 cells were treated by PS-341 for 0, 3, 6, 9, and 24 h. Extraction of total RNA was carried out using Trizol reagent (Life Technologies, Inc., Grand Island, NY, USA) according to the manufacturer's instructions. DNA was removed by DNase. RNA (2 mg) was reverse-transcribed with random primers (Life Technologies Inc.) and Superscriptt II reverse transcriptase (Life Technologies Inc.). The cDNA was used for real-time PCR.
Real-time RT-PCR
Real-time PCR was performed on the iCycler iQt system (BioRad, Hercules, CA, USA). The PCR product is measured via a fluorescent signal generated by the binding of the fluorophore SybrGreen during the PCR. The amplification was followed by 40 cycles with 941C for 20 s, 601C for 10 s, 651C for 25 s, and a fluorescence read step at 831C for 25 s. We used the GAPDH cDNA to normalize the expression data of Bcl-2 and Bcl-xl. The gene expression in control sample was given 100%, and the PS-341-treated samples were compared to the control sample. GAPDH primers: gagtcaacggatttggtcg (forward), tggaagatggtgatggga (reverse); Bcl-2 primers: ccccgttacttttcctctg (forward), ccctctgcgacagcttata (reverse); Bcl-xl primers: ggagctggtggttgactttc (forward), ctccgattcagtcccttctg (reverse). All experiments were carried out in triplicate.
Transfections and reporter assays
The NF-kB reporter construct (pGL3-NF-kB) containing four copies of the NF-kB site was cloned into the pGL3-basic plasmid (Promega) (generous gift of Moshe Arditi, MD, Department of Pediatrics Infectious Diseases, Cedars-Sinai Medical Center). T98G cells were placed into 24-well plates and incubated until they reached 60-80% confluence. Cells were transfected with pGL3-NF-kB and pRL-SV40-Luciferase (Renilla luciferase) plasmids using the Geneporter transfection reagent (Qiagen, Valencia, CA, USA). After 3 h, cells were exposed to PS-341 (10 À7 M, 24 h). Luciferase activity in cell lysates was measured by Dual Luciferase assay system (Promega, Madison, WI, USA), and this was normalized by renilla activity. Cell survival, proliferation Figure 11 Drug interactions between the PS-341 and either tumor necrosis factor (TNF) a or TNF-related apoptosis-inducing ligand (TRAIL) in GBM. Both TRAIL and TNFa bind to their respective receptors, and activate the caspase apoptotic pathway, as well as, stimulate NF-kB activation (Franco et al., 2001; Dai et al., 2003) . Activation of NF-kB can attenuate the apoptosis induced by the stimuli (Wang et al., 1998) . The proteasome inhibitor, PS-341, blocks degradation of IkB and thus inhibits the nuclear translocation of NF-kB; therefore, the activation of the caspase pathway is unfettered by the NF-kB progrowth effects. (Franco et al., 2001; An et al., 2003) PS-341 induces growth arrest and apoptosis in GBM D Yin et al
